FVFIGP
Flagship Ventures Fund IV General Partner Portfolio holdings
AUM
$585M
1 Year Est. Return
–
AUM
$585M
AUM Growth
–
Holding
5
Top Buys
| 1 | +$368M | |
| 2 | +$121M | |
| 3 | +$87.2M | |
| 4 |
TTOO
T2 Biosystems, Inc
TTOO
|
+$5.85M |
| 5 |
CARM
Carisma Therapeutics
CARM
|
+$2.46M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Seres Therapeutics
MCRB
$127M
| $368M | 62.99% |
+634,144
|
|
||
2
Editas Medicine
EDIT
$222M
| $121M | 20.67% |
+4,955,316
|
|
||
|
SYRS
3
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $87.2M | 14.92% |
+480,666
|
|
||
|
TTOO
4
DELISTED
T2 Biosystems, Inc
TTOO
| $5.85M | 1% |
+148
|
|
||
|
CARM
5
DELISTED
Carisma Therapeutics
CARM
| $2.46M | 0.42% |
+73,321
|
|